AXIM Biotechnologies, Inc. announced that its nutraceutical division AXIM® Wellness has launched its newest cannabinoid-based chewing gum product, Workout Gum. The Company will also be expanding its nutraceutical product line, AXIM® Wellness Gum (Wellness Gum), within the coming weeks with two additional cannabinoid-based chewing gum products, Hangover Gum and Hole-in-One Gum. Workout Gum combines 5 mg of full-spectrum hemp-derived cannabidiol (CBD) per piece with caffeine and ginseng for increased energy and magnesium citrate to relieve fatigue and promote muscle growth. It’s more instant than a cup of coffee and much more convenient for those who are on-the-go. Gyms, fitness retailers and personal trainers will have access to bulk ordering and wholesale pricing of Workout Gum through the Wellness Gum wholesale program. The program also offers participants the opportunity to earn commission on sales made online or in stores. Hole-in-One Gum is formulated with 5 mg of full-spectrum hemp-derived CBD with magnesium citrate, caffeine, ginseng, sage extract and wild green oat extract to power golfers through all 18 holes and help them stay focused. The gum is specifically formulated to help golfers improve their athletic endurance through a combination of caffeine, muscle-relieving magnesium citrate, attention-enhancing sage extract, and wild green oat extract to enhance cognitive function. Hangover Gum provides 5 mg of full-spectrum hemp-derived CBD, feverfew, caffeine ginseng and magnesium citrate to aid consumers in pushing through low energy levels and post-party aches to feel more like their fully-alert and active selves. Recovery doesn’t have to include greasy food and pain relief medications with this fast-acting gum.
Axim Biotechnologies, Inc. is a vertically integrated research and development company. The Company is focused on improving the landscape for the diagnosis of ophthalmological conditions such as dry eye disease (DED) through rapid diagnostic tests. Its core competencies include development of rapid lateral flow immunoassays, reagents, and monoclonal antibody development for such assays. Its product categories include Eye Health, wherein the Company acquired two FDA cleared tests for dye eye disease and has internally developed a third assay; and SARS-CoV-2 neutralizing antibody tests. The Company is focused on developing a proprietary diagnostic platform that can be adapted to test for a variety of analytes including SARS-Cov-2, Lactoferrin, IgE, Lacritin, and MMP-9. Its platform capability can also be applied to rapid testing for vaccine candidates. Its platform can also be used to enable point-of-care detection for one or more cancers using a unique cancer biomarker, QSOX1-L.